"Real world" eligibility for aducanumab

被引：28
|
作者：
Canevelli, Marco [1 ,2 ]
Rossi, Paolo Dionigi [3 ]
Astrone, Paolo [4 ]
Consorti, Ernesto [5 ]
Vanacore, Nicola [2 ]
Cesari, Matteo [6 ,7 ]
机构：
[1] Sapienza Univ, Dept Human Neurosci, Viale Univ 30, I-00185 Rome, Italy
[2] Natl Inst Hlth, Natl Ctr Dis Prevent & Hlth Promot, Rome, Italy
[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Geriatr Unit, Milan, Italy
[4] Azienda Socio Sanit Terr ASST Lodi, Subacute Care Unit, Lodi, Italy
[5] Univ Milan, Geriatr & Gerontol, Milan, Italy
[6] IRCCS Ist Clin Sci Maugeri, Geriatr Unit, Milan, Italy
[7] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2021年 / 69卷 / 10期
关键词：
D O I：
10.1111/jgs.17390
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：2995 / 2998
页数：4
相关论文
共 50 条
  • [21] Identifying candidates for real-world peanut oral immunotherapy: eligibility and barriers to participation
    Blackman, A.
    Anagnostou, A.
    ALLERGY, 2021, 76 : 353 - 353
  • [22] Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
    Knopman, David S.
    Perlmutter, Joel S.
    NEUROLOGY, 2021, 97 (11) : 545 - 547
  • [23] Outcomes of ECLS-SHOCK Eligibility Criteria Applied to a Real-World Cohort
    von Lewinski, Dirk
    Herold, Lukas
    Bachl, Eva
    Bugger, Heiko
    Glantschnig, Theresa
    Kolesnik, Ewald
    Verheyen, Nicolas
    Benedikt, Martin
    Wallner, Markus
    von Lewinski, Friederike
    Schmidt, Albrecht
    Harb, Stefan
    Ablasser, Klemens
    Sacherer, Michael
    Scherr, Daniel
    Manninger-Wuenscher, Martin
    Paetzold, Sascha
    Gollmer, Johannes
    Zirlik, Andreas
    Toth, Gabor G.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (22)
  • [24] Missing data in the eligibility criteria of synthetic controls from real-world data
    Li, Liang
    Jemielita, Thomas
    Chen, Cong
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2025,
  • [25] Evaluating eligibility criteria of oncology trials using real-world data and AI
    Ruishan Liu
    Shemra Rizzo
    Samuel Whipple
    Navdeep Pal
    Arturo Lopez Pineda
    Michael Lu
    Brandon Arnieri
    Ying Lu
    William Capra
    Ryan Copping
    James Zou
    Nature, 2021, 592 : 629 - 633
  • [26] MAPPING REAL-WORLD ANKYLOSINC SPONDYLITIS PATIENTS TO CLINICAL TRIAL ELIGIBILITY CRITERIA
    Sholter, Dalton
    Inman, Robert
    Masetto, Ariel
    Rahman, Proton
    Rampakakis, Emmanouil
    Asin-Milan, Odalis
    Rachich, Meagan
    Nantel, Francois
    Lehman, Allen J.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 26 - 27
  • [27] Mapping Real-World Ankylosing Spondylitis Patients to Clinical Trial Eligibility Criteria
    Sholter, Dalton
    Inman, Robert
    Masetto, Ariel
    Rahman, Proton
    Rampakakis, Emmanouil
    Asin-Milan, Odalis
    Rachich, Meagan
    Nantel, Francois
    Lehman, Allen
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1101 - 1101
  • [28] Mapping Real-World Psoriatic Arthritis Patients to Clinical Trial Eligibility Criteria
    Arendse, Regan
    Haaland, Derek
    Fortin, Isabelle
    Rahman, Proton
    Rampakakis, Emmanouil
    Asin-Milan, Odalis
    Rachich, Meagan
    Nantel, Francois
    Lehman, Allen
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1035 - 1036
  • [29] Mapping Real-World Rheumatoid Arthritis Patients to Clinical Trial Eligibility Criteria
    Keystone, Edward
    Olszynski, Wojciech
    Bessette, Louis
    Rahman, Proton
    Rampakakis, Emmanouil
    Lehman, Allen
    Asin-Milan, Odalis
    Nantel, Francois
    Rachich, Meagan
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1107 - 1108
  • [30] Eligibility criteria for Sacubitril-Valsartan in patients admitted for heart failure: the real world
    David Cabrita Roque, D.
    Augusto, J.
    Santos, M.
    Candeias Faria, D.
    Baltazar Ferreira, J.
    Sacchetti, A.
    Melo, L.
    Oliveira Soares, A.
    Morais, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 477 - 478
12345